Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant RP2 + Nivolumab in Resectable Melanoma
NCT07862530Phase 2Not yet recruiting
- Start
- Dec 2026
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
A Phase 2 trial of sturlimogene erparepvec in melanoma. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
sturlimogene erparepvec
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT07862530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07862530.